TRPC3 (Transient Receptor Potential Canonical 3) is a member of the TRP family of cation channels, which play critical roles in cellular calcium (Ca²⁺) signaling. It functions as a non-selective cation channel permeable to Ca²⁺ and Na⁺, and is activated by phospholipase C (PLC)-coupled receptors, contributing to diverse physiological processes such as neuronal excitability, cardiovascular regulation, and cell proliferation. TRPC3 is widely expressed in tissues, including the brain, heart, and immune cells, and its dysregulation has been implicated in neurodegenerative diseases, hypertension, and cancer. Research on TRPC3 often focuses on its structural dynamics, regulatory mechanisms (e.g., interactions with proteins like calmodulin or STIM1), and its role in disease pathways.
TRPC3 antibodies are essential tools for studying the expression, localization, and function of this channel. They are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect TRPC3 protein levels in cell lysates or tissue sections. High-quality antibodies are validated for specificity, often through knockout controls, to minimize cross-reactivity with other TRP isoforms (e.g., TRPC6 or TRPC7). Recent studies also employ TRPC3 antibodies in co-immunoprecipitation assays to investigate protein-protein interactions or post-translational modifications. As TRPC3 gains attention as a therapeutic target, these antibodies support drug discovery efforts by enabling the assessment of channel modulation in disease models. Researchers prioritize antibodies with well-documented batch consistency and application-specific validation to ensure reproducibility in experimental outcomes.